Effect of CoQ10 on the Outcome of MAFLD Patients
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorAin Shams University
About this trial
So far there has been no universal treatment for MAFLD since it has a complex etiology that involves ethnic, genetic, metabolic and environmental factors. However, therapeutic life changes including: diet, weight loss, and physical activity remain the cornerstone of treatment and is recommended by both American and European associations.
Inflammatory biomarkers, such as tumor necrosis factor-alpha, and adipokines play key roles in the pathogenesis of MAFLD, hence, the anti-inflammatory and antioxidant effects of coenzyme Q10 especially at high doses that have not been tested are hypothesized to have a beneficial role in improving the systemic inflammation and biochemical variables.
This study is conducted to test this hypothesis
Eligibility criteria
Qualifiers
Waist circumference (WC) ≥ 102/88 cm for men and women respectively.
HDL cholesterol <40 mg/dl in men and <50 mg/dl in women or on specific drug therapy.
Plasma Triglycerides ≥ 150 mg/dl or on specific drug therapy.
Blood pressure ≥130 and/or ≥ 85 or on specific anti-hypertensive therapy.
Disqualifiers
Pregnancy or lactating
Physical or mental abnormalities
HCV infection
HBV infection
Trial design
Treatments tested in this trial
- Coenzyme Q10 Forte® capsules
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
1National Hepatology and tropical medicine research institute Cairo Egypt
Sponsors and collaborators
Ain Shams University
Lead sponsor
Source ClinicalTrials.gov